Inhibiting inhibitory pathways in human gd T cells

Blood

Volumn 122, Issue 6, 2013, Pages 857-858

  Lopez, Richard D ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B AND T LYMPHOCYTE ATTENUATOR; CELL PROTEIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HERPESVIRUS ENTRY MEDIATOR; PROGRAMMED DEATH 1 RECEPTOR; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; BTLA PROTEIN, HUMAN; IMMUNOGLOBULIN RECEPTOR;

ADAPTIVE IMMUNITY; ANTINEOPLASTIC ACTIVITY; GAMMA DELTA T LYMPHOCYTE; HUMAN; INNATE IMMUNITY; INTRACELLULAR SIGNALING; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLFIERATION; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; GENE EXPRESSION REGULATION; HODGKIN DISEASE; IMMUNOLOGY; NONHODGKIN LYMPHOMA; NOTE; PHYSIOLOGY; T LYMPHOCYTE SUBPOPULATION;

GENE EXPRESSION REGULATION, NEOPLASTIC; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; RECEPTORS, IMMUNOLOGIC; T-LYMPHOCYTE SUBSETS;

EID: 84886874186     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-06-506584     Document Type: Short Survey

References (10)

1. Gertner-Dardenne J., Fauriat C, Orlanducci F., et al. The co-receptor BTLA negatively regulates human Vg9Vd2 T cell proliferation: a potential way of immune escape for lymphoma cells. Blood. 2013; 122(6): 922-931.
2. Watanabe N, Gavrieli M, Sedy J.R., et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol. 2003; 4(7): 670-679. (Pubitemid 36874444)
3. Kabelitz D, Wesch D, He W. Perspectives of gd T cells in tumor immunology. Cancer Res. 2007; 67(1): 5-8.
4. Silva-Santos B., Schamel WW, Fisch P, Eberl M. gd T-cell conference 2012: close encounters for the fifth time. Eur J Immunol. 2012; 42(12): 3101-3105.
5. Vantourout P, Hayday A. Six-of-the-best: unique contributions of gd T cells to immunology. Nat Rev Immunol. 2013; 13(2): 88-100.
6. Hannani D, Ma Y, Yamazaki T., Déchanet-Merville J, Kroemer G, Zitvogel L. Harnessing gd T cells in anticancer immunotherapy. Trends Immunol. 2012; 33(5): 199-206.
7. Topalian SL, Hodi FS, Brahmer J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26): 2443-2454.
8. Brahmer JR, Tykodi SS, Chow L.Q., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26): 2455-2465.
9. Murphy TL, Murphy KM. Slow down and survive: Enigmatic immunoregulation by BTLA and HVEM. Annu Rev Immunol. 2010; 28: 389-411.
10. Wilhelm M, Kunzmann V, Eckstein S., et al. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood. 2003; 102(1): 200-206. (Pubitemid 36759655)